Phase I Randomized, Assessor-Blinded Study on Skin Irritation and Sensitization of 5% Lidocaine Medicated Plaster in Healthy Volunteers

The primary objective of this Phase I study is to evaluate the **skin irritation** and **sensitization potential** of a novel 5% **lidocaine** medicated plaster in healthy volunteers. This assessment is clinically relevant as it helps determine the safety profile of the medicated plaster, ensuring it does not cause adverse dermatological reactions in users. Understanding the irritation and sensitization potential is crucial for the development of safe topical anesthetic products. No secondary objectives are provided for this study.

The clinical trial involves a study population of **healthy subjects** with no specific medical conditions. The trial includes both male and female participants, encompassing an **age range** that includes adults and older adults. The total number of participants has not been disclosed by the sponsor. The trial population was selected to exclude vulnerable populations, ensuring a focus on individuals without significant health issues. Lifestyle considerations such as diet, physical activity, and habits have not been specified. The sponsor has not provided detailed information regarding the key inclusion or exclusion criteria for this study.

The clinical trial is designed as a **randomized**, assessor-blinded, controlled study involving healthy volunteers. The primary aim is to evaluate the skin irritation and sensitization potential of a novel 5% lidocaine medicated plaster. The trial is categorized as a Phase I study, focusing on safety and tolerability in a healthy population. The trial is expected to commence recruitment on May 5, 2025, and conclude by November 3, 2025, with an overall duration of approximately six months.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit. During this visit, eligibility criteria will be assessed to ensure participants meet the study requirements. Following successful screening, participants will be randomized into the study groups. The trial will include multiple follow-up visits to monitor the participants' skin reactions and any adverse events. These visits are crucial for assessing the primary endpoints related to skin irritation and sensitization. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to gather comprehensive data on the plaster's effects.

The expected length of participant involvement is contingent upon the study schedule, with each participant anticipated to remain in the trial for the full duration unless specific conditions necessitate early termination. Such conditions may include the occurrence of significant adverse events or withdrawal of consent by the participant. The study's design ensures that all procedures are conducted in a manner that prioritizes participant safety and data integrity, adhering to the highest standards of clinical research methodology.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess the efficacy of the investigational treatment in a Phase 3 study. The trial is scheduled to commence recruitment on May 5, 2025, with an estimated completion date of November 3, 2025. The efficacy of the treatment will be evaluated through predefined primary and secondary endpoints, although specific endpoints are not detailed in the provided data. The trial will follow a structured methodology to ensure the accurate collection and analysis of efficacy data, adhering to the standards expected in a Phase 3 clinical trial. The trial's design and execution will be aligned with regulatory requirements to ensure the reliability and validity of the efficacy assessments.